O	0	13	Miscellaneous	Miscellaneous	JJ	B-NP
O	14	22	Proteins	Protein	NNS	I-NP

O	23	28	Apart	Apart	RB	B-ADVP
O	29	33	from	from	IN	B-PP
O	34	37	the	the	DT	B-NP
O	38	43	above	above	RB	I-NP
O	43	44	-	-	HYPH	I-NP
O	44	53	described	describe	VBN	I-NP
O	54	62	proteins	protein	NNS	I-NP
O	62	63	,	,	,	O
O	64	71	several	several	JJ	B-NP
O	72	77	other	other	JJ	I-NP
O	78	87	molecules	molecule	NNS	I-NP
O	88	91	are	be	VBP	B-VP
O	92	96	also	also	RB	I-VP
O	97	107	associated	associate	VBN	I-VP
O	108	112	with	with	IN	B-PP
O	113	116	the	the	DT	B-NP
B-Pathological_formation	117	129	pathological	pathological	JJ	I-NP
I-Pathological_formation	130	137	lesions	lesion	NNS	I-NP
O	138	140	of	of	IN	B-PP
O	141	143	AD	AD	NN	B-NP
O	143	144	,	,	,	O
O	145	148	and	and	CC	O
O	149	153	some	some	DT	B-NP
O	154	156	of	of	IN	B-PP
O	157	162	these	these	DT	B-NP
O	163	166	can	can	MD	B-VP
O	167	169	be	be	VB	I-VP
O	170	178	regarded	regard	VBN	I-VP
O	179	181	as	as	IN	B-PP
O	182	189	amateur	amateur	JJ	B-NP
O	190	200	chaperones	chaperone	NNS	I-NP
O	200	201	.	.	.	O

O	202	207	Acute	Acute	JJ	B-NP
O	208	213	phase	phase	NN	I-NP
O	214	222	proteins	protein	NNS	I-NP
O	222	223	,	,	,	O
O	224	228	such	such	JJ	B-PP
O	229	231	as	as	IN	I-PP
O	232	238	alpha1	alpha1	NN	B-NP
O	238	239	-	-	HYPH	O
O	239	255	antichymotrypsin	antichymotrypsin	NN	B-NP
O	256	257	(	(	(	O
O	257	260	ACT	ACT	NN	B-NP
O	260	261	)	)	)	O
O	261	262	,	,	,	O
O	263	269	alpha2	alpha2	NN	B-NP
O	269	270	-	-	HYPH	O
O	270	283	macroglobulin	macroglobulin	NN	B-NP
O	284	285	(	(	(	O
O	285	292	alpha2M	alpha2M	NN	B-NP
O	292	293	)	)	)	O
O	293	294	,	,	,	O
O	295	298	and	and	CC	O
O	299	302	SAP	SAP	NN	B-NP
O	302	303	,	,	,	O
O	304	307	are	be	VBP	B-VP
O	308	311	all	all	DT	O
O	312	322	associated	associate	VBN	B-VP
O	323	327	with	with	IN	B-PP
O	328	333	Abeta	Abeta	NN	B-NP
O	334	344	deposition	deposition	NN	I-NP
O	345	346	[	[	(	O
O	346	349	129	129	CD	B-NP
O	349	350	-	-	HYPH	I-NP
O	350	353	132	132	CD	I-NP
O	353	354	]	]	)	O
O	354	355	.	.	.	O

O	356	359	ACT	ACT	NN	B-NP
O	360	362	is	be	VBZ	B-VP
O	363	364	a	a	DT	B-NP
O	365	371	serine	serine	NN	I-NP
O	372	380	protease	protease	NN	I-NP
O	381	390	inhibitor	inhibitor	NN	I-NP
O	391	393	of	of	IN	B-PP
O	394	397	the	the	DT	B-NP
O	398	404	serpin	serpin	NN	I-NP
O	405	411	family	family	NN	I-NP
O	411	412	,	,	,	O
O	413	416	and	and	CC	O
O	417	419	in	in	IN	B-PP
O	420	422	AD	AD	NN	B-NP
O	422	423	,	,	,	O
O	424	427	ACT	ACT	NN	B-NP
O	428	434	levels	level	NNS	I-NP
O	435	438	are	be	VBP	B-VP
O	439	450	upregulated	upregulate	VBN	I-VP
O	450	451	,	,	,	O
O	452	455	and	and	CC	O
O	456	463	binding	binding	NN	B-NP
O	464	466	of	of	IN	B-PP
O	467	470	ACT	ACT	NN	B-NP
O	471	475	with	with	IN	B-PP
O	476	481	Abeta	Abeta	NN	B-NP
O	482	489	induces	induce	VBZ	B-VP
O	490	495	Abeta	Abeta	NN	B-NP
O	496	511	fibrillogenesis	fibrillogenesis	NN	I-NP
O	512	513	[	[	(	O
O	513	516	133	133	CD	B-NP
O	516	517	-	-	HYPH	I-NP
O	517	520	135	135	CD	I-NP
O	520	521	]	]	)	O
O	521	522	.	.	.	O

O	523	534	Furthermore	Furthermore	RB	B-ADVP
O	534	535	,	,	,	O
O	536	540	when	when	WRB	B-ADVP
O	541	544	ACT	ACT	NN	B-NP
O	545	547	is	be	VBZ	B-VP
O	548	561	overexpressed	overexpresse	VBN	I-VP
O	562	564	in	in	IN	B-PP
O	565	575	transgenic	transgenic	JJ	B-NP
O	576	580	mice	mouse	NNS	I-NP
O	580	581	,	,	,	O
O	582	584	an	an	DT	B-NP
O	585	594	increased	increase	VBN	I-NP
B-Pathological_formation	595	601	plaque	plaque	NN	I-NP
O	602	606	load	load	NN	I-NP
O	607	609	in	in	IN	B-PP
O	610	613	the	the	DT	B-NP
B-Organ	614	620	brains	brain	NNS	I-NP
O	621	623	of	of	IN	B-PP
O	624	629	these	these	DT	B-NP
O	630	634	mice	mouse	NNS	I-NP
O	635	638	and	and	CC	O
O	639	647	impaired	impaired	JJ	B-NP
O	648	655	spatial	spatial	JJ	I-NP
O	656	664	learning	learning	NN	I-NP
O	665	667	is	be	VBZ	B-VP
O	668	676	observed	observe	VBN	I-VP
O	677	678	[	[	(	O
O	678	681	134	134	CD	B-NP
O	681	682	,	,	,	I-NP
O	683	686	135	135	CD	I-NP
O	686	687	]	]	)	O
O	687	688	.	.	.	O

O	689	696	alpha2M	alpha2M	NN	B-NP
O	697	701	also	also	RB	B-ADVP
O	702	707	binds	bind	VBZ	B-VP
O	708	713	Abeta	Abeta	NN	B-NP
O	713	714	,	,	,	O
O	715	723	although	although	IN	B-SBAR
O	724	726	in	in	IN	B-PP
O	727	735	contrast	contrast	NN	B-NP
O	736	738	to	to	TO	B-PP
O	739	742	ACT	ACT	NN	B-NP
O	742	743	,	,	,	O
O	744	748	this	this	DT	B-NP
O	749	756	binding	binding	NN	I-NP
O	757	765	prevents	prevent	VBZ	B-VP
O	766	771	Abeta	Abeta	NN	B-NP
B-Cellular_component	772	778	fibril	fibril	NN	I-NP
O	779	788	formation	formation	NN	I-NP
O	789	792	and	and	CC	I-NP
B-Cellular_component	793	799	fibril	fibril	NN	I-NP
O	799	800	-	-	HYPH	O
O	800	810	associated	associate	VBN	B-NP
O	811	824	neurotoxicity	neurotoxicity	NN	I-NP
O	825	826	[	[	(	O
O	826	829	136	136	CD	B-NP
O	829	830	,	,	,	I-NP
O	831	834	137	137	CD	I-NP
O	834	835	]	]	)	O
O	835	836	.	.	.	O

O	837	844	alpha2M	alpha2M	NN	B-NP
O	845	853	promotes	promote	VBZ	B-VP
O	854	857	the	the	DT	B-NP
O	858	866	protease	protease	NN	I-NP
O	866	867	-	-	HYPH	B-VP
O	867	875	mediated	mediate	VBN	B-NP
O	876	887	degradation	degradation	NN	I-NP
O	888	890	of	of	IN	B-PP
O	891	898	alpha2M	alpha2M	NN	B-NP
O	898	899	/	/	SYM	B-NP
O	899	904	Abeta	Abeta	NN	I-NP
O	905	914	complexes	complex	NNS	I-NP
O	915	918	and	and	CC	O
O	919	930	contributes	contribute	VBZ	B-VP
O	931	933	to	to	TO	B-PP
O	934	943	clearance	clearance	NN	B-NP
O	944	946	of	of	IN	B-PP
O	947	952	Abeta	Abeta	NN	B-NP
O	953	957	from	from	IN	B-PP
O	958	961	the	the	DT	B-NP
B-Organ	962	967	brain	brain	NN	I-NP
O	968	969	(	(	(	O
O	969	978	discussed	discuss	VBN	B-VP
O	979	981	in	in	IN	B-PP
O	982	991	paragraph	paragraph	NN	B-NP
O	992	993	4	4	CD	I-NP
O	993	994	)	)	)	O
O	995	996	[	[	(	O
O	996	999	138	138	CD	B-NP
O	999	1000	,	,	,	I-NP
O	1001	1004	139	139	CD	I-NP
O	1004	1005	]	]	)	O
O	1005	1006	.	.	.	O

O	1007	1010	The	The	DT	B-NP
O	1011	1023	glycoprotein	glycoprotein	NN	I-NP
O	1024	1027	SAP	SAP	NN	I-NP
O	1028	1035	belongs	belong	VBZ	B-VP
O	1036	1038	to	to	TO	B-PP
O	1039	1042	the	the	DT	B-NP
O	1043	1052	pentraxin	pentraxin	NN	I-NP
O	1053	1059	family	family	NN	I-NP
O	1060	1063	and	and	CC	O
O	1064	1066	is	be	VBZ	B-VP
O	1067	1068	a	a	DT	B-NP
O	1069	1075	common	common	JJ	I-NP
O	1076	1085	component	component	NN	I-NP
O	1086	1088	of	of	IN	B-PP
O	1089	1092	all	all	DT	B-NP
O	1093	1098	known	know	VBN	I-NP
O	1099	1104	types	type	NNS	I-NP
O	1105	1107	of	of	IN	B-PP
B-Cellular_component	1108	1115	amyloid	amyloid	JJ	B-NP
I-Cellular_component	1116	1123	fibrils	fibril	NNS	I-NP
O	1123	1124	.	.	.	O

O	1125	1128	SAP	SAP	NN	B-NP
O	1129	1131	is	be	VBZ	B-VP
O	1132	1143	upregulated	upregulate	VBN	I-VP
O	1144	1146	in	in	IN	B-PP
O	1147	1149	AD	AD	NN	B-NP
O	1150	1153	and	and	CC	O
O	1154	1162	protects	protect	VBZ	B-VP
B-Cellular_component	1163	1170	amyloid	amyloid	JJ	B-NP
I-Cellular_component	1171	1178	fibrils	fibril	NNS	I-NP
O	1179	1183	from	from	IN	B-PP
O	1184	1195	proteolysis	proteolysis	NN	B-NP
O	1196	1198	in	in	FW	B-ADVP
O	1199	1204	vitro	vitro	FW	I-ADVP
O	1205	1206	[	[	(	O
O	1206	1209	140	140	CD	B-NP
O	1209	1210	,	,	,	I-NP
O	1211	1214	141	141	CD	I-NP
O	1214	1215	]	]	)	O
O	1215	1216	.	.	.	O

O	1217	1220	SAP	SAP	NN	B-NP
O	1221	1224	not	not	RB	B-CONJP
O	1225	1229	only	only	RB	I-CONJP
O	1230	1241	colocalizes	colocalize	VBZ	B-VP
O	1242	1246	with	with	IN	B-PP
O	1247	1250	SPs	SP	NNS	B-NP
O	1251	1254	and	and	CC	O
O	1255	1264	interacts	interact	VBZ	B-VP
O	1265	1269	with	with	IN	B-PP
O	1270	1280	aggregated	aggregate	VBN	B-NP
O	1281	1286	Abeta	Abeta	NN	I-NP
O	1286	1287	;	;	:	O
O	1288	1291	SAP	SAP	NN	B-NP
O	1292	1301	oligomers	oligomer	NNS	I-NP
O	1302	1306	also	also	RB	B-ADVP
O	1307	1311	bind	bind	VBP	B-VP
O	1312	1315	and	and	CC	I-VP
O	1316	1324	activate	activate	VBP	I-VP
O	1325	1327	C1	C1	NN	B-NP
O	1328	1329	[	[	(	O
O	1329	1332	142	142	CD	B-NP
O	1332	1333	]	]	)	O
O	1333	1334	.	.	.	O

O	1335	1339	Both	Both	CC	O
O	1340	1342	C1	C1	NN	B-NP
O	1343	1346	and	and	CC	I-NP
O	1347	1350	SAP	SAP	NN	I-NP
O	1351	1354	may	may	MD	B-VP
O	1355	1359	bind	bind	VB	I-VP
O	1360	1362	to	to	TO	B-PP
B-Cellular_component	1363	1372	fibrillar	fibrillar	JJ	B-NP
O	1373	1378	Abeta	Abeta	NN	I-NP
O	1379	1387	deposits	deposit	NNS	I-NP
O	1388	1390	in	in	FW	B-ADVP
O	1391	1395	vivo	vivo	FW	I-ADVP
O	1396	1399	and	and	CC	O
O	1400	1406	induce	induce	VB	B-VP
B-Cell	1407	1417	microglial	microglial	JJ	B-NP
O	1418	1428	activation	activation	NN	I-NP
O	1428	1429	,	,	,	O
O	1430	1432	as	as	IN	B-SBAR
O	1433	1441	cultured	culture	VBN	B-NP
O	1442	1447	human	human	JJ	I-NP
B-Cell	1448	1458	microglial	microglial	JJ	I-NP
I-Cell	1459	1464	cells	cell	NNS	I-NP
O	1465	1469	show	show	VBP	B-VP
O	1470	1472	an	an	DT	B-NP
O	1473	1481	increase	increase	NN	I-NP
O	1482	1484	in	in	IN	B-PP
O	1485	1493	cytokine	cytokine	NN	B-NP
O	1494	1504	production	production	NN	I-NP
O	1505	1510	after	after	IN	B-PP
O	1511	1513	co	co	AFX	B-NP
O	1513	1514	-	-	HYPH	I-NP
O	1514	1525	stimulation	stimulation	NN	I-NP
O	1526	1528	of	of	IN	B-PP
O	1529	1534	Abeta	Abeta	NN	B-NP
O	1535	1539	with	with	IN	B-PP
O	1540	1543	C1q	C1q	NN	B-NP
O	1544	1547	and	and	CC	I-NP
O	1548	1551	SAP	SAP	NN	I-NP
O	1552	1553	[	[	(	O
O	1553	1556	104	104	CD	B-NP
O	1556	1557	]	]	)	O
O	1557	1558	.	.	.	O

O	1559	1564	These	These	DT	B-NP
O	1565	1577	observations	observation	NNS	I-NP
O	1578	1585	further	further	RB	B-ADVP
O	1586	1596	strengthen	strengthen	VBP	B-VP
O	1597	1600	the	the	DT	B-NP
O	1601	1606	above	above	RB	I-NP
O	1606	1607	-	-	HYPH	I-NP
O	1607	1612	noted	note	VBN	I-NP
O	1613	1623	suggestion	suggestion	NN	I-NP
O	1624	1628	that	that	IN	B-NP
O	1629	1632	not	not	RB	B-CONJP
O	1633	1637	only	only	RB	I-CONJP
O	1638	1643	Abeta	Abeta	NN	B-NP
O	1643	1644	,	,	,	O
O	1645	1648	but	but	CC	B-CONJP
O	1649	1653	also	also	RB	I-CONJP
O	1654	1661	several	several	JJ	B-NP
O	1662	1667	Abeta	Abeta	NN	I-NP
O	1667	1668	-	-	HYPH	B-VP
O	1668	1675	binding	bind	VBG	B-NP
O	1676	1684	proteins	protein	NNS	I-NP
O	1684	1685	,	,	,	O
O	1686	1689	are	be	VBP	B-VP
O	1690	1697	capable	capable	JJ	B-ADJP
O	1698	1700	of	of	IN	B-PP
O	1701	1711	activating	activate	VBG	B-VP
O	1712	1715	the	the	DT	B-NP
O	1716	1726	complement	complement	NN	I-NP
O	1727	1733	system	system	NN	I-NP
O	1733	1734	,	,	,	O
O	1735	1738	and	and	CC	O
O	1739	1743	thus	thus	RB	O
O	1743	1744	,	,	,	O
O	1745	1755	contribute	contribute	VBP	B-VP
O	1756	1758	to	to	TO	B-PP
O	1759	1776	neuroinflammation	neuroinflammation	NN	B-NP
O	1777	1779	in	in	IN	B-PP
O	1780	1782	AD	AD	NN	B-NP
O	1782	1783	.	.	.	O

O	1784	1786	In	In	IN	B-PP
O	1787	1795	addition	addition	NN	B-NP
O	1795	1796	,	,	,	O
O	1797	1801	both	both	CC	O
O	1802	1809	alpha2M	alpha2M	NN	B-NP
O	1810	1813	and	and	CC	I-NP
O	1814	1817	ACT	ACT	NN	I-NP
O	1817	1818	,	,	,	O
O	1819	1821	in	in	IN	B-PP
O	1822	1830	contrast	contrast	NN	B-NP
O	1831	1833	to	to	TO	B-PP
O	1834	1837	SAP	SAP	NN	B-NP
O	1837	1838	,	,	,	O
O	1839	1842	can	can	MD	B-VP
O	1843	1845	be	be	VB	I-VP
O	1846	1854	regarded	regard	VBN	I-VP
O	1855	1857	as	as	IN	B-PP
O	1858	1865	amateur	amateur	JJ	B-NP
O	1866	1876	chaperones	chaperone	NNS	I-NP
O	1876	1877	,	,	,	O
O	1878	1880	as	as	IN	B-SBAR
O	1881	1885	they	they	PRP	B-NP
O	1886	1894	regulate	regulate	VBP	B-VP
O	1895	1909	conformational	conformational	JJ	B-NP
O	1910	1917	changes	change	NNS	I-NP
O	1918	1920	of	of	IN	B-PP
O	1921	1926	Abeta	Abeta	NN	B-NP
O	1926	1927	.	.	.	O

O	1928	1934	Tissue	Tissue	NN	B-NP
O	1934	1935	-	-	HYPH	I-NP
O	1935	1939	type	type	NN	I-NP
O	1940	1951	plasminogen	plasminogen	NN	I-NP
O	1952	1961	activator	activator	NN	I-NP
O	1962	1963	(	(	(	O
O	1963	1966	tPA	tPA	NN	B-NP
O	1966	1967	)	)	)	O
O	1968	1977	regulates	regulate	VBZ	B-VP
O	1978	1988	activation	activation	NN	B-NP
O	1989	1991	of	of	IN	B-PP
O	1992	2003	plasminogen	plasminogen	NN	B-NP
O	2004	2008	into	into	IN	B-PP
O	2009	2016	plasmin	plasmin	NN	B-NP
O	2017	2020	and	and	CC	O
O	2021	2023	is	be	VBZ	B-VP
O	2024	2033	expressed	express	VBN	I-VP
O	2034	2036	in	in	IN	B-PP
O	2037	2044	various	various	JJ	B-NP
O	2045	2052	regions	region	NNS	I-NP
O	2053	2055	of	of	IN	B-PP
O	2056	2059	the	the	DT	B-NP
B-Organ	2060	2065	brain	brain	NN	I-NP
O	2066	2076	especially	especially	RB	B-ADVP
O	2077	2079	in	in	IN	B-PP
O	2080	2083	the	the	DT	B-NP
B-Multi-tissue_structure	2084	2095	hippocampus	hippocampus	NN	I-NP
O	2096	2097	[	[	(	O
O	2097	2100	143	143	CD	B-NP
O	2100	2101	]	]	)	O
O	2101	2102	.	.	.	O

O	2103	2110	Several	Several	JJ	B-NP
O	2111	2118	reports	report	NNS	I-NP
O	2119	2128	suggested	suggest	VBD	B-VP
O	2129	2131	an	an	DT	B-NP
O	2132	2141	important	important	JJ	I-NP
O	2142	2146	role	role	NN	I-NP
O	2147	2150	for	for	IN	B-PP
O	2151	2154	tPA	tPA	NN	B-NP
O	2155	2157	in	in	IN	B-PP
O	2158	2160	AD	AD	NN	B-NP
O	2160	2161	,	,	,	O
O	2162	2164	as	as	IN	B-SBAR
O	2165	2168	the	the	DT	B-NP
O	2169	2172	tPA	tPA	NN	I-NP
O	2173	2179	system	system	NN	I-NP
O	2180	2182	is	be	VBZ	B-VP
O	2183	2191	involved	involve	VBN	I-VP
O	2192	2194	in	in	IN	B-PP
O	2195	2200	Abeta	Abeta	NN	B-NP
O	2201	2209	turnover	turnover	NN	I-NP
O	2210	2211	[	[	(	O
O	2211	2214	144	144	CD	B-NP
O	2214	2215	,	,	,	I-NP
O	2216	2219	145	145	CD	I-NP
O	2219	2220	]	]	)	O
O	2220	2221	.	.	.	O

B-Cellular_component	2222	2231	Fibrillar	Fibrillar	JJ	B-NP
O	2232	2237	forms	form	NNS	I-NP
O	2238	2240	of	of	IN	B-PP
O	2241	2246	Abeta	Abeta	NN	B-NP
O	2247	2256	stimulate	stimulate	VBP	B-VP
O	2257	2260	tPA	tPA	NN	B-NP
O	2261	2269	activity	activity	NN	I-NP
O	2270	2272	in	in	FW	B-ADVP
O	2273	2278	vitro	vitro	FW	I-ADVP
O	2278	2279	,	,	,	O
O	2280	2287	whereas	whereas	IN	O
O	2288	2290	in	in	IN	B-PP
O	2291	2293	AD	AD	NN	B-NP
O	2294	2302	patients	patient	NNS	I-NP
O	2302	2303	,	,	,	O
O	2304	2305	a	a	DT	B-NP
O	2306	2315	reduction	reduction	NN	I-NP
O	2316	2318	of	of	IN	B-PP
O	2319	2322	tPA	tPA	NN	B-NP
O	2323	2331	activity	activity	NN	I-NP
O	2332	2334	is	be	VBZ	B-VP
O	2335	2343	observed	observe	VBN	I-VP
O	2344	2346	in	in	IN	B-PP
O	2347	2350	the	the	DT	B-NP
O	2351	2359	affected	affect	VBN	I-NP
O	2360	2365	areas	area	NNS	I-NP
O	2366	2367	[	[	(	O
O	2367	2370	144	144	CD	B-NP
O	2370	2371	,	,	,	I-NP
O	2372	2375	146	146	CD	I-NP
O	2375	2376	]	]	)	O
O	2376	2377	.	.	.	O

O	2378	2386	Although	Although	IN	B-SBAR
O	2387	2390	tPA	tPA	NN	B-NP
O	2391	2394	has	have	VBZ	B-VP
O	2395	2397	no	no	DT	B-NP
O	2398	2404	effect	effect	NN	I-NP
O	2405	2407	on	on	IN	B-PP
O	2408	2422	conformational	conformational	JJ	B-NP
O	2423	2430	changes	change	NNS	I-NP
O	2431	2433	of	of	IN	B-PP
O	2434	2439	Abeta	Abeta	NN	B-NP
O	2439	2440	,	,	,	O
O	2441	2443	it	it	PRP	B-NP
O	2444	2449	might	might	MD	B-VP
O	2450	2454	play	play	VB	I-VP
O	2455	2456	a	a	DT	B-NP
O	2457	2461	role	role	NN	I-NP
O	2462	2464	in	in	IN	B-PP
O	2465	2468	the	the	DT	B-NP
O	2469	2478	clearance	clearance	NN	I-NP
O	2479	2481	of	of	IN	B-PP
O	2482	2487	Abeta	Abeta	NN	B-NP
O	2488	2492	from	from	IN	B-PP
O	2493	2496	the	the	DT	B-NP
B-Organ	2497	2502	brain	brain	NN	I-NP
O	2503	2504	(	(	(	O
O	2504	2513	paragraph	paragraph	NN	B-NP
O	2514	2515	4	4	CD	I-NP
O	2515	2516	]	]	)	O
O	2516	2517	.	.	.	O

O	2518	2521	The	The	DT	B-NP
O	2522	2527	actin	actin	NN	I-NP
O	2527	2528	-	-	HYPH	I-NP
O	2528	2538	regulatory	regulatory	JJ	I-NP
O	2539	2546	protein	protein	NN	I-NP
O	2547	2555	gelsolin	gelsolin	NN	I-NP
O	2556	2558	is	be	VBZ	B-VP
O	2559	2564	found	find	VBN	I-VP
O	2565	2569	both	both	CC	O
B-Cell	2570	2585	intracellularly	intracellularly	RB	B-ADVP
O	2586	2589	and	and	CC	O
O	2590	2592	in	in	IN	B-PP
B-Organism_substance	2593	2599	plasma	plasma	NN	B-NP
O	2600	2601	[	[	(	O
O	2601	2604	147	147	CD	B-NP
O	2604	2605	,	,	,	I-NP
O	2606	2609	148	148	CD	I-NP
O	2609	2610	]	]	)	O
O	2610	2611	.	.	.	O

B-Organism_substance	2612	2618	Plasma	Plasma	NN	B-NP
O	2619	2627	gelsolin	gelsolin	NN	I-NP
O	2628	2631	can	can	MD	B-VP
O	2632	2634	be	be	VB	I-VP
O	2635	2645	considered	consider	VBN	I-VP
O	2646	2648	an	an	DT	B-NP
O	2649	2656	amateur	amateur	JJ	I-NP
O	2657	2666	chaperone	chaperone	NN	I-NP
O	2666	2667	,	,	,	O
O	2668	2670	as	as	IN	B-SBAR
O	2671	2673	it	it	PRP	B-NP
O	2674	2679	binds	bind	VBZ	B-VP
O	2680	2685	Abeta	Abeta	NN	B-NP
O	2686	2689	and	and	CC	O
O	2690	2693	not	not	RB	B-CONJP
O	2694	2698	only	only	RB	I-CONJP
O	2699	2707	inhibits	inhibit	VBZ	B-VP
O	2708	2711	its	its	PRP$	B-NP
O	2712	2717	Abeta	Abeta	NN	I-NP
O	2718	2732	fibrillization	fibrillization	NN	I-NP
O	2733	2736	but	but	CC	O
O	2737	2739	is	be	VBZ	B-VP
O	2740	2744	also	also	RB	B-ADVP
O	2745	2752	capable	capable	JJ	B-ADJP
O	2753	2755	of	of	IN	B-PP
O	2756	2765	degrading	degrade	VBG	B-VP
O	2766	2775	preformed	preformed	JJ	B-NP
O	2776	2781	Abeta	Abeta	NN	I-NP
B-Cellular_component	2782	2789	fibrils	fibril	NNS	I-NP
O	2790	2791	[	[	(	O
O	2791	2794	149	149	CD	B-NP
O	2794	2795	,	,	,	I-NP
O	2796	2799	150	150	CD	I-NP
O	2799	2800	]	]	)	O
O	2800	2801	.	.	.	O

O	2802	2813	Furthermore	Furthermore	RB	B-ADVP
O	2813	2814	,	,	,	O
O	2815	2823	gelsolin	gelsolin	NN	B-NP
O	2824	2832	inhibits	inhibit	VBZ	B-VP
O	2833	2838	Abeta	Abeta	NN	B-NP
O	2838	2839	-	-	HYPH	O
O	2839	2847	mediated	mediate	VBN	B-NP
O	2848	2861	neurotoxicity	neurotoxicity	NN	I-NP
O	2862	2863	[	[	(	O
O	2863	2866	151	151	CD	B-NP
O	2866	2867	]	]	)	O
O	2867	2868	.	.	.	O

O	2869	2872	One	One	CD	B-NP
O	2873	2875	of	of	IN	B-PP
O	2876	2879	the	the	DT	B-NP
O	2880	2885	major	major	JJ	I-NP
O	2886	2898	gangliosides	ganglioside	NNS	I-NP
O	2899	2901	in	in	IN	B-PP
O	2902	2905	the	the	DT	B-NP
B-Organ	2906	2911	brain	brain	NN	I-NP
O	2912	2914	is	be	VBZ	B-VP
O	2915	2918	GM1	GM1	NN	B-NP
O	2918	2919	.	.	.	O

O	2920	2927	Soluble	Soluble	JJ	B-NP
O	2928	2933	Abeta	Abeta	NN	I-NP
O	2934	2939	binds	bind	VBZ	B-VP
O	2940	2943	GM1	GM1	NN	B-NP
O	2944	2947	and	and	CC	O
O	2948	2951	the	the	DT	B-NP
O	2952	2958	formed	form	VBN	I-NP
O	2959	2968	complexes	complex	NNS	I-NP
O	2969	2979	accelerate	accelerate	VBP	B-VP
O	2980	2985	Abeta	Abeta	NN	B-NP
O	2986	3001	fibrillogenesis	fibrillogenesis	NN	I-NP
O	3002	3004	by	by	IN	B-PP
O	3005	3011	acting	act	VBG	B-VP
O	3012	3014	as	as	IN	B-PP
O	3015	3016	a	a	DT	B-NP
O	3017	3021	seed	seed	NN	I-NP
O	3022	3025	for	for	IN	B-PP
O	3026	3031	Abeta	Abeta	NN	B-NP
O	3032	3033	[	[	(	O
O	3033	3036	152	152	CD	B-NP
O	3036	3037	]	]	)	O
O	3037	3038	.	.	.	O

O	3039	3041	In	In	IN	B-PP
O	3042	3045	the	the	DT	B-NP
O	3046	3054	presence	presence	NN	I-NP
O	3055	3057	of	of	IN	B-PP
O	3058	3061	GM1	GM1	NN	B-NP
O	3061	3062	,	,	,	O
O	3063	3068	Abeta	Abeta	NN	B-NP
O	3069	3071	is	be	VBZ	B-VP
O	3072	3076	more	more	RBR	B-ADJP
O	3077	3087	neurotoxic	neurotoxic	JJ	I-ADJP
O	3088	3092	than	than	IN	B-PP
O	3093	3098	Abeta	Abeta	NN	B-NP
O	3099	3104	alone	alone	RB	B-ADVP
O	3104	3105	,	,	,	O
O	3106	3109	and	and	CC	O
O	3110	3121	cholesterol	cholesterol	NN	B-NP
O	3121	3122	-	-	HYPH	B-NP
O	3122	3126	rich	rich	JJ	I-NP
B-Cellular_component	3127	3136	membranes	membrane	NNS	I-NP
O	3137	3148	demonstrate	demonstrate	VBP	B-VP
O	3149	3160	accelerated	accelerate	VBN	I-VP
O	3161	3166	Abeta	Abeta	NN	B-NP
O	3167	3174	binding	binding	NN	I-NP
O	3175	3178	due	due	JJ	B-ADJP
O	3179	3181	to	to	TO	B-PP
O	3182	3185	the	the	DT	B-NP
O	3186	3195	formation	formation	NN	I-NP
O	3196	3198	of	of	IN	B-PP
O	3199	3202	GM1	GM1	NN	B-NP
O	3203	3211	clusters	cluster	NNS	I-NP
O	3212	3213	[	[	(	O
O	3213	3216	153	153	CD	B-NP
O	3216	3217	,	,	,	I-NP
O	3218	3221	154	154	CD	I-NP
O	3221	3222	]	]	)	O
O	3222	3223	.	.	.	O

O	3224	3226	As	As	IN	B-SBAR
O	3227	3230	GM1	GM1	NN	B-NP
O	3231	3233	is	be	VBZ	B-VP
O	3234	3235	a	a	DT	B-NP
O	3236	3241	major	major	JJ	I-NP
O	3242	3251	component	component	NN	I-NP
O	3252	3254	of	of	IN	B-PP
B-Organism_substance	3255	3260	lipid	lipid	NN	B-NP
I-Organism_substance	3261	3266	rafts	raft	NNS	I-NP
O	3267	3270	and	and	CC	O
O	3271	3277	recent	recent	JJ	B-NP
O	3278	3285	studies	study	NNS	I-NP
O	3286	3293	suggest	suggest	VBP	B-VP
O	3294	3298	that	that	IN	B-SBAR
O	3299	3304	Abeta	Abeta	NN	B-NP
O	3305	3317	accumulation	accumulation	NN	I-NP
O	3318	3320	in	in	IN	B-PP
O	3321	3326	these	these	DT	B-NP
B-Organism_substance	3327	3332	lipid	lipid	NN	I-NP
I-Organism_substance	3333	3338	rafts	raft	NNS	I-NP
O	3339	3341	is	be	VBZ	B-VP
O	3342	3344	an	an	DT	B-NP
O	3345	3350	early	early	JJ	I-NP
O	3351	3356	event	event	NN	I-NP
O	3357	3359	in	in	IN	B-PP
O	3360	3362	AD	AD	NN	B-NP
O	3363	3374	development	development	NN	I-NP
O	3374	3375	,	,	,	O
O	3376	3379	GM1	GM1	NN	B-NP
O	3380	3385	might	might	MD	B-VP
O	3386	3390	play	play	VB	I-VP
O	3391	3393	an	an	DT	B-NP
O	3394	3403	important	important	JJ	I-NP
O	3404	3408	role	role	NN	I-NP
O	3409	3411	in	in	IN	B-PP
O	3412	3415	the	the	DT	B-NP
O	3416	3421	early	early	JJ	I-NP
O	3422	3427	steps	step	NNS	I-NP
O	3428	3430	in	in	IN	B-PP
O	3431	3433	AD	AD	NN	B-NP
O	3434	3446	pathogenesis	pathogenesis	NN	I-NP
O	3447	3448	[	[	(	O
O	3448	3451	155	155	CD	B-NP
O	3451	3452	,	,	,	I-NP
O	3453	3456	156	156	CD	I-NP
O	3456	3457	]	]	)	O
O	3457	3458	.	.	.	O

O	3459	3461	In	In	IN	B-PP
O	3462	3469	summary	summary	NN	B-NP
O	3469	3470	,	,	,	O
O	3471	3478	several	several	JJ	B-NP
O	3479	3487	proteins	protein	NNS	I-NP
O	3488	3491	are	be	VBP	B-VP
O	3492	3502	associated	associate	VBN	I-VP
O	3503	3507	with	with	IN	B-PP
O	3508	3513	Abeta	Abeta	NN	B-NP
O	3514	3524	aggregates	aggregate	NNS	I-NP
O	3525	3527	in	in	IN	B-PP
O	3528	3531	the	the	DT	B-NP
B-Organ	3532	3534	AD	AD	NN	I-NP
I-Organ	3535	3540	brain	brain	NN	I-NP
O	3541	3544	and	and	CC	O
O	3545	3555	contribute	contribute	VBP	B-VP
O	3556	3558	to	to	TO	B-PP
O	3559	3562	the	the	DT	B-NP
O	3563	3574	aggregation	aggregation	NN	I-NP
O	3575	3577	of	of	IN	B-PP
O	3578	3583	Abeta	Abeta	NN	B-NP
O	3584	3587	and	and	CC	O
O	3588	3594	should	should	MD	B-VP
O	3594	3595	,	,	,	O
O	3596	3605	therefore	therefore	RB	B-ADVP
O	3605	3606	,	,	,	O
O	3607	3609	be	be	VB	B-VP
O	3610	3620	considered	consider	VBN	I-VP
O	3621	3623	as	as	IN	B-PP
O	3624	3631	amateur	amateur	JJ	B-NP
O	3632	3642	chaperones	chaperone	NNS	I-NP
O	3642	3643	.	.	.	O

O	3644	3646	In	In	IN	B-PP
O	3647	3655	addition	addition	NN	B-NP
O	3655	3656	,	,	,	O
O	3657	3661	they	they	PRP	B-NP
O	3662	3667	might	might	MD	B-VP
O	3668	3672	play	play	VB	I-VP
O	3673	3674	a	a	DT	B-NP
O	3675	3679	role	role	NN	I-NP
O	3680	3682	in	in	IN	B-PP
O	3683	3693	triggering	trigger	VBG	B-VP
O	3694	3706	inflammation	inflammation	NN	B-NP
O	3706	3707	.	.	.	O

